Astellas sues Impax over US Flomax patent
This article was originally published in Scrip
Executive Summary
Japan's Astellas Pharmahas filed suit against Impaxin the US District Court for the Northern District of California, alleging infringement related to its generic version of the benign prostatic hyperplasia treatment Flomax (tamsulosin HCl), thus triggering a 30-month stay of approval while the legal challenge is fought. The lawsuit was filed jointly with Boehringer Ingelheim's US subsidiary, which co-markets the product in the US.